95%Confidence
0Views
FDASource
2026-04-18Date
Summary
Further sterility assurance failures for K.C. Pharmaceuticals' dry eye relief products demonstrate comprehensive manufacturing quality breakdown. The multiple distributor network amplifies the market impact and regulatory exposure.
Actionable: Coordinate with all affected distributors for comprehensive product recall and customer notification procedures.
AI Confidence: 95%
Data Points
firmK.C. Pharmaceuticals, Inc
classificationClass II
statusOngoing
distributionNationwide in the US
productDry Eye Relief Eye Drops, (glycerin 0.2%, hypromellose 0.2% and polyethylene glycol 400 1%) 0.5 FL OZ (15 mL) bottles; a) GERI CARE, Distributed by:
Get Signals Instantly
Premium subscribers receive every signal via Telegram the moment it fires — hours before it appears here.
Subscribe Now